Adamas Pharmaceuticals, Inc. (ADMS) Posts Earnings Results, Misses Estimates By $0.03 EPS
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) issued its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.01) by ($0.03), Briefing.com reports. During the same period in the prior year, the company posted ($0.66) earnings per share. The firm’s revenue for the quarter was down 99.3% compared to the same quarter last year.
Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) traded up $1.38 during trading on Friday, reaching $28.00. The company’s stock had a trading volume of 2,367,929 shares, compared to its average volume of 1,230,941. The company has a quick ratio of 11.79, a current ratio of 11.79 and a debt-to-equity ratio of 0.32.
Several research firms recently commented on ADMS. BidaskClub cut Adamas Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 17th. ValuEngine raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Noble Financial reaffirmed a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, August 9th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $30.00 target price on shares of Adamas Pharmaceuticals in a research note on Wednesday, September 20th. Finally, JMP Securities reaffirmed an “outperform” rating and set a $33.00 target price (up previously from $29.00) on shares of Adamas Pharmaceuticals in a research note on Friday, August 25th. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $39.50.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.